These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9237497)

  • 41. Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.
    Lopez JR; Kaura V; Diggle CP; Hopkins PM; Allen PD
    Br J Anaesth; 2018 Oct; 121(4):953-961. PubMed ID: 30236258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.
    Tammaro A; Di Martino A; Bracco A; Cozzolino S; Savoia G; Andria B; Cannavo A; Spagnuolo M; Piluso G; Aurino S; Nigro V
    Clin Genet; 2011 May; 79(5):438-47. PubMed ID: 20681998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle.
    Richter M; Schleithoff L; Deufel T; Lehmann-Horn F; Herrmann-Frank A
    J Biol Chem; 1997 Feb; 272(8):5256-60. PubMed ID: 9030597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
    Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
    Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
    Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
    Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
    MacLennan DH; Duff C; Zorzato F; Fujii J; Phillips M; Korneluk RG; Frodis W; Britt BA; Worton RG
    Nature; 1990 Feb; 343(6258):559-61. PubMed ID: 1967823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.
    Rueffert H; Olthoff D; Deutrich C; Schober R; Froster UG
    Am J Med Genet A; 2004 Jan; 124A(3):248-54. PubMed ID: 14708096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF; Girard T; Censier K; Urwyler A
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
    Islander G; Bendixen D; Ranklev-Twetman E; Ording H
    Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
    Heytens L
    Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
    Steinfath M; Scholz J; Singh S; Wappler F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Modern diagnostic approaches to malignant hyperthermia susceptibility].
    Kazantseva AA; Lebedinskiĭ KM
    Anesteziol Reanimatol; 2014; 59(4):64-8. PubMed ID: 25549489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.